Skip to content

Study · Observational study · 2026

3 results

The CrescNet Registry Achondroplasia Module: Real-World Demographic Data and Clinical Outcomes in Untreated and Vosoritide-Treated Individuals.

Mohnike K, Beger C, Gausche R, Hoyer-Kuhn H, Muschol N, Palm K, Rohrer TR, Sredkova M, Streata I, Wechsung K, Woelfle J, Zeman J and 4 more

Show all authors

Eibenstein U, Pimenta JM, Reichert A, Pfäffle R

Hormone research in paediatrics30 Jan 2026Cited by 1 (Europe PMC)

PMID41615893 (opens in a new tab)PMCIDPMC13046303 (opens in a new tab)DOI10.1159/000550795 (opens in a new tab)PepBankPUB-41615893
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with achondroplasia receiving vosoritide, untreated-ACH-referenced mean height SD score increased from baseline at 1 year (p ≤ 0.0001).

    In plain wordsIn children with achondroplasia receiving vosoritide, average height SD score was higher at one year than baseline.

    Peptide
    Vosoritide
    Outcome
    IncreaseHeight SD score at year 1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    p-value
    ≤ 0.0001
    height SD score versus baseline, 1 year after initiation

    Source sentences

    Summary
    In vosoritide-treated individuals, mean height standard deviation score, referenced to an untreated European achondroplasia population, significantly increased from baseline at 1, 2, and 3 years after vosoritide initiation (p ≤ 0.0001).
    2 context sentences
    Summary · context
    Pseudonymized data were sent to the CrescNet central database, Leipzig University Hospital, Germany, for analysis by age and treatment status.
    Summary · context
    Data from 73 untreated and 186 vosoritide-treated individuals with genetically documented achondroplasia were analyzed.
  2. 02HumanObservational studyEfficacy outcome

    In children with achondroplasia receiving vosoritide, untreated-ACH-referenced mean height SD score increased from baseline at 2 years (p ≤ 0.0001).

    In plain wordsIn children with achondroplasia receiving vosoritide, average height SD score was higher at two years than baseline.

    Peptide
    Vosoritide
    Outcome
    IncreaseHeight SD score at year 2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    p-value
    ≤ 0.0001
    height SD score versus baseline, 2 years after initiation

    Source sentences

    Summary
    In vosoritide-treated individuals, mean height standard deviation score, referenced to an untreated European achondroplasia population, significantly increased from baseline at 1, 2, and 3 years after vosoritide initiation (p ≤ 0.0001).
    2 context sentences
    Summary · context
    Pseudonymized data were sent to the CrescNet central database, Leipzig University Hospital, Germany, for analysis by age and treatment status.
    Summary · context
    Data from 73 untreated and 186 vosoritide-treated individuals with genetically documented achondroplasia were analyzed.
  3. 03HumanObservational studyEfficacy outcome

    In children with achondroplasia receiving vosoritide, untreated-ACH-referenced mean height SD score increased from baseline at 3 years (p ≤ 0.0001).

    In plain wordsIn children with achondroplasia receiving vosoritide, average height SD score was higher at three years than baseline.

    Peptide
    Vosoritide
    Outcome
    IncreaseHeight SD score at year 3
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    p-value
    ≤ 0.0001
    height SD score versus baseline, 3 years after initiation

    Source sentences

    Summary
    In vosoritide-treated individuals, mean height standard deviation score, referenced to an untreated European achondroplasia population, significantly increased from baseline at 1, 2, and 3 years after vosoritide initiation (p ≤ 0.0001).
    2 context sentences
    Summary · context
    Pseudonymized data were sent to the CrescNet central database, Leipzig University Hospital, Germany, for analysis by age and treatment status.
    Summary · context
    Data from 73 untreated and 186 vosoritide-treated individuals with genetically documented achondroplasia were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.